The central nervous system-focused drug developer has raised approximately $124m so far from investors including 3M.

Impel NeuroPharma, a US-based central nervous system drug developer backed by manufacturing group 3M, has filed to raise $75m in an initial public offering on the Nasdaq Global Market. Founded in 2008, Impel is developing therapies for patients with central nervous system disorders. It has also developed a medical device that delivers medicine to the…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.